Advertisement News Archives - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

News

January 9, 2026

Santhera grants Agamree rights to Nxera for DMD

Santhera Pharmaceuticals has entered an exclusive licensing agreement with Nxera Pharma for Agamree (Vamorolone) to treat Duchenne muscular dystrophy (DMD) in Australia, Japan, New Zealand, and South Korea.

Santhera grants Agamree rights to Nxera for DMD